AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28762354 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐office bleaching with 35% hydrogen peroxide (HP) activated by LED bleaching unit
Number of subjects: 90
Study 28762354 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel microabrasion (EM) followed by in‐office bleaching with 44% carbamide peroxide gel
Number of subjects: 90
Study 28762354 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐office bleaching with 5% sodium hypochlorite (5% NaOCl)
Number of subjects: 90
Study 28762354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching and microabrasion procedures
Number of subjects: 90
Study 28762354 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative satisfaction
Number of subjects: 90
Study 25633498 — intervention group
Group type: EXPERIMENTAL
Intervention: HO-RUTF
Number of subjects: 141
Study 25633498 — intervention group
Group type: COMPARATOR
Intervention: RUTF
Number of subjects: 141
Study 23463625 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine/oxaliplatin (CapOx) plus bevacizumab
Number of subjects: 255
Study 23463625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab
Number of subjects: 255
Study 21297287 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive arm task
Number of subjects: 32
Study 21297287 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional shoulder measures
Number of subjects: 32
Study 21297287 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate (HR) and power output (PO)
Number of subjects: 32
Study 19815264 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 200
Study 19815264 — intervention group
Group type: COMPARATOR
Intervention: Ureteroscopy (URS)
Number of subjects: 200
Study 16674031 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored sip test
Number of subjects: 0
Study 16674031 — intervention group
Group type: COMPARATOR
Intervention: Routine cautious introduction of fluids
Number of subjects: 0
Study 16674031 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored sip test and routine cautious introduction of fluids
Number of subjects: 0
Study 12931937 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood group
Number of subjects: 214
Study 12931937 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood group
Number of subjects: 214
Study 12931937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mood subscales
Number of subjects: 214
Study 10869913 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anesthesia (G1)
Number of subjects: 42
Study 10869913 — intervention group
Group type: COMPARATOR
Intervention: Opioid anesthesia (G2)
Number of subjects: 42
Study 8924193 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg citalopram infusion
Number of subjects: 8
Study 8924193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 1531952 — intervention group
Group type: EXPERIMENTAL
Intervention: Zabicipril
Number of subjects: 6
Study 1531952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3891362 — intervention group
Group type: COMPARATOR
Intervention: Dihydroxybusulfan (B) 600 mg/m2 p.o. for 4-6 weeks q 12 weeks
Number of subjects: 156
Study 3891362 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (C) 150 mg/m2 p.o. for 7 days q 4 weeks
Number of subjects: 156
Study 3891362 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (Cyclophosphamide 400 mg/m2 i.v., doxorubicin 30 mg/m2, 5-fluorouracil 400 mg/m2 i.v., days 1 and 8 q 4 weeks)
Number of subjects: 156
Study 3891362 — intervention group
Group type: COMPARATOR
Intervention: Pelvic irradiation (for stage IIB patients)
Number of subjects: 156
Study 3891362 — intervention group
Group type: COMPARATOR
Intervention: Second-look laparotomy
Number of subjects: 156
Study 31584944 — intervention group
Group type: EXPERIMENTAL
Intervention: Wirelessly observed therapy (WOT)
Number of subjects: 77
Study 31584944 — intervention group
Group type: COMPARATOR
Intervention: Directly observed therapy (DOT)
Number of subjects: 77
Study 29904986 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 898
Study 29904986 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 898
Study 29904986 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher health literacy
Number of subjects: 898
Study 26987589 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 70
Study 26987589 — intervention group
Group type: COMPARATOR
Intervention: avastin
Number of subjects: 70
Study 24502469 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a specialist cardiometabolic health care nurse
Number of subjects: 0
Study 24502469 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist cardiometabolic health care nurse
Number of subjects: 0
Study 21898066 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic microwave diathermy (MD)
Number of subjects: 40
Study 21898066 — intervention group
Group type: COMPARATOR
Intervention: Sham microwave diathermy (MD)
Number of subjects: 40
Study 20551194 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that mentioned adverse drug reactions (ADRs)
Number of subjects: 107
Study 20551194 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that used standardised methods for disclosure of ADRs
Number of subjects: 107
Study 20551194 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that tabulated adverse drug reactions
Number of subjects: 107
Study 20551194 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that stated numbers of and reasons for withdrawal
Number of subjects: 107
Study 20551194 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs that reported safety data adequately according to Consort guidelines
Number of subjects: 107
Study 20551194 — intervention group
Group type: COMPARATOR
Intervention: Influence of registration on reporting
Number of subjects: 107
Study 20551194 — intervention group
Group type: COMPARATOR
Intervention: Influence of sponsoring on reporting
Number of subjects: 107
Study 17284729 — intervention group
Group type: EXPERIMENTAL
Intervention: Television watching
Number of subjects: 0
Study 17284729 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel food (French fries)
Number of subjects: 0
Study 17284729 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous television show
Number of subjects: 0
Study 17284729 — intervention group
Group type: COMPARATOR
Intervention: No television
Number of subjects: 0
Study 17284729 — intervention group
Group type: COMPARATOR
Intervention: Repeated segment of a television show
Number of subjects: 0
Study 16146472 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Ketamine (PK group)
Number of subjects: 276
Study 16146472 — intervention group
Group type: COMPARATOR
Intervention: Propofol/Alfentanil (PA group)
Number of subjects: 276
Study 16146472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 276
Study 14578018 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (ear and body)
Number of subjects: 34
Study 11246561 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 U TNF-alpha
Number of subjects: 8
Study 9566100 — intervention group
Group type: EXPERIMENTAL
Intervention: H15 (3600 mg daily)
Number of subjects: 37
Study 9566100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9566100 — intervention group
Group type: EXPERIMENTAL
Intervention: H15
Number of subjects: 37
Study 7827399 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 microgram twice daily
Number of subjects: 622
Study 7827399 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 to 1.0 micrograms/day plus calcium 1000 mg/day
Number of subjects: 622
Study 7827399 — intervention group
Group type: COMPARATOR
Intervention: Elemental calcium 1000 mg/day
Number of subjects: 622
Study 3137320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume enteral feeds (12 ml/kg/day) in addition to parenteral alimentation for 10 days starting on day 8 of life
Number of subjects: 46
Study 3137320 — intervention group
Group type: COMPARATOR
Intervention: Parenteral alimentation alone until day 18 of life
Number of subjects: 46
Study 30017510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle–foot orthosis (AFO)
Number of subjects: 52
Study 30017510 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged shoes
Number of subjects: 52
Study 30017510 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional unloader brace
Number of subjects: 52
Study 30017510 — intervention group
Group type: COMPARATOR
Intervention: Control (own shoes)
Number of subjects: 52
Study 28095259 — intervention group
Group type: EXPERIMENTAL
Intervention: British Columbia Adult Mental Health Practice Support Program
Number of subjects: 111
Study 28095259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 26335904 — intervention group
Group type: EXPERIMENTAL
Intervention: Light sedation (BIS 70-80)
Number of subjects: 200
Study 26335904 — intervention group
Group type: COMPARATOR
Intervention: Deep sedation (BIS < 60)
Number of subjects: 200
Study 23476752 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention with moderate-intensity physical activity
Number of subjects: 0
Study 23476752 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to healthy food
Number of subjects: 0
Study 23476752 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio
Number of subjects: 0
Study 21513604 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-targeted noninvasive ventilation (NIV)
Number of subjects: 16
Study 21513604 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-targeted noninvasive ventilation (NIV)
Number of subjects: 16
Study 18307077 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraceptive pills (ECP), condoms, and an information leaflet
Number of subjects: 420
Study 18307077 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 420
Study 17139825 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant inhalations (700 mg cumulative dose over 8 weeks) during chemotherapy
Number of subjects: 140
Study 17139825 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (control group)
Number of subjects: 140
Study 12540551 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nasal immunization with CRM197 in chitosan delivery system
Number of subjects: 0
Study 12540551 — intervention group
Group type: EXPERIMENTAL
Intervention: Second nasal immunization with CRM197 in chitosan delivery system
Number of subjects: 0
Study 12540551 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular vaccine
Number of subjects: 0
Study 12540551 — intervention group
Group type: COMPARATOR
Intervention: Intranasal immunization with CRM197 without chitosan
Number of subjects: 0
Study 12540551 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral intranasal immunization
Number of subjects: 0
Study 12540551 — intervention group
Group type: EXPERIMENTAL
Intervention: Second immunization
Number of subjects: 0
Study 10890906 — intervention group
Group type: EXPERIMENTAL
Intervention: Three frequencies used in the first experiment
Number of subjects: 0
Study 10890906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine frequencies used in the second experiment
Number of subjects: 0
Study 10890906 — intervention group
Group type: EXPERIMENTAL
Intervention: Five frequencies used in the third experiment
Number of subjects: 0
Study 8731520 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg THA (tacrine)
Number of subjects: 12
Study 8731520 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg THA (tacrine)
Number of subjects: 12
Study 8731520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1414965 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23
Study 1414965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29706227 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA‐SC self‐injection
Number of subjects: 30
Study 28514347 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment using ABO anthropometric system with indirect bonding
Number of subjects: 32
Study 28514347 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthodontic treatment protocol
Number of subjects: 32
Study 25560575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine 0.1mg/kg
Number of subjects: 370
Study 25560575 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% normal saline)
Number of subjects: 370
Study 23621161 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 143
Study 23621161 — intervention group
Group type: COMPARATOR
Intervention: mycophenolate
Number of subjects: 143
Study 23621161 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose statins
Number of subjects: 143
Study 20889053 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-force chincup (125-250 g)
Number of subjects: 26
Study 20889053 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad-helix appliance with chincup
Number of subjects: 26
Study 20889053 — intervention group
Group type: EXPERIMENTAL
Intervention: Chincup only
Number of subjects: 26
Study 20889053 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated Class III)
Number of subjects: 26
Study 19882741 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational health intervention program to reduce WBV exposure, implemented for 7 months.
Number of subjects: 126
Study 19882741 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual group (control group).
Number of subjects: 126
Study 16782094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 30
Study 16782094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15128463 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for antithrombotic therapy
Number of subjects: 0
Study 15128463 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 11740232 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1 treatment
Number of subjects: 7
Study 11740232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9006424 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide (Diamox)
Number of subjects: 40
Study 9006424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride (Trusopt)
Number of subjects: 40
Study 9006424 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide added to dorzolamide
Number of subjects: 40
Study 9006424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide added to acetazolamide
Number of subjects: 40
Study 8215566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 39
Study 8215566 — intervention group
Group type: COMPARATOR
Intervention: Plasma protein fraction
Number of subjects: 39
Study 3321873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 223
Study 3321873 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 223
Study 3321873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amniotomy and oxytocin
Number of subjects: 223
Study 3321873 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 223
Study 3321873 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy added to oxytocin
Number of subjects: 223
Study 3321873 — intervention group
Group type: COMPARATOR
Intervention: Bishop score
Number of subjects: 223
Study 28632915 — intervention group
Group type: EXPERIMENTAL
Intervention: WCRF‐NL health promotion materials
Number of subjects: 226
Study 28632915 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study 27535127 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil-based mayonnaise (SB-mayo)
Number of subjects: 0
Study 27535127 — intervention group
Group type: COMPARATOR
Intervention: Palm olein-based mayonnaise (PO-mayo)
Number of subjects: 0
Study 27535127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SB-mayo and PO-mayo
Number of subjects: 0
Study 25062801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tools for Getting Along (TFGA) curriculum
Number of subjects: 720
Study 25062801 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 720
Study 22905823 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased VSTM load (manipulated by increased set size)
Number of subjects: 0
Study 22905823 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual detection experiments
Number of subjects: 0
Study 21118617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed n‐3/n‐6 PUFA diets
Number of subjects: 8
Study 21118617 — intervention group
Group type: COMPARATOR
Intervention: n‐6 specific PUFA diets
Number of subjects: 8
Study 21118617 — intervention group
Group type: COMPARATOR
Intervention: RCT substituting n‐6 PUFA for TFA and SFA without increasing n‐3 PUFA
Number of subjects: 8
Study 18521101 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 gauge needles
Number of subjects: 204
Study 18521101 — intervention group
Group type: COMPARATOR
Intervention: 18 gauge needles
Number of subjects: 204
Study 15994254 — intervention group
Group type: EXPERIMENTAL
Intervention: PR‐SHAM
Number of subjects: 32
Study 15994254 — intervention group
Group type: EXPERIMENTAL
Intervention: PR‐IMT
Number of subjects: 32
Study 15994254 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 12812678 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) solution
Number of subjects: 42
Study 12812678 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 42
Study 12812678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 10566563 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily for 10 days)
Number of subjects: 542
Study 10566563 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg twice daily for 10 days)
Number of subjects: 542
Study 10566563 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 542
Study 10566563 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 542
Study 8912230 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg)
Number of subjects: 8
Study 8912230 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine (20 mg)
Number of subjects: 8
Study 8912230 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone (20 mg)
Number of subjects: 8
Study 8912230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1841020 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine
Number of subjects: 4
Study 1841020 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance nifedipine therapy
Number of subjects: 4
Study 1841020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 4
Study 1841020 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 4
Study 6356628 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg pirlindol
Number of subjects: 10
Study 6356628 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pirlindol
Number of subjects: 10
Study 6356628 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg pirlindol
Number of subjects: 10
Study 6356628 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg imipramine
Number of subjects: 10
Study 6356628 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tranylcypromine
Number of subjects: 10
Study 6356628 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg nomifensine
Number of subjects: 10
Study 6356628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31050161 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide-metformin
Number of subjects: 41
Study 31050161 — intervention group
Group type: COMPARATOR
Intervention: placebo-metformin
Number of subjects: 41
Study 28673277 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-based assay with a 15-min webinar
Number of subjects: 129
Study 28673277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no assay results)
Number of subjects: 129
Study 25697725 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Number of subjects: 497
Study 25697725 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 497
Study 23538170 — intervention group
Group type: EXPERIMENTAL
Intervention: MABA 400 μg once daily
Number of subjects: 50
Study 23538170 — intervention group
Group type: EXPERIMENTAL
Intervention: MABA 1200 μg once daily
Number of subjects: 50
Study 23538170 — intervention group
Group type: EXPERIMENTAL
Intervention: TIO + SAL (tiotropium 18 μg once daily plus salmeterol 50 μg twice daily)
Number of subjects: 50
Study 23538170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21434341 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Jiangzhuo Granule (YJG)
Number of subjects: 53
Study 21434341 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 19551272 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 alternate daily preprandial measurements
Number of subjects: 21
Study 19551272 — intervention group
Group type: COMPARATOR
Intervention: 2 alternate daily pre‐ and postprandial measurements
Number of subjects: 21
Study 17537842 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 (a ghrelin analog)
Number of subjects: 0
Study 17537842 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 0
Study 17537842 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 0
Study 17537842 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant GHRP-2
Number of subjects: 0
Study 17537842 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant GHRH
Number of subjects: 0
Study 17537842 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 0
Study 12811566 — intervention group
Group type: EXPERIMENTAL
Intervention: IT(100%) - Intermittent training at 100% of vVO(2max)
Number of subjects: 7